Regeneron Pharmaceuticals Inc.

REGN ·Healthcare, Drug Manufacturers - General, United States

Regeneron Pharmaceuticals, Inc. (REGN)

Overview

Regeneron Pharmaceuticals is a biotechnology company headquartered in Tarrytown, New York, that discovers, develops, manufactures, and commercializes medicines for serious diseases, operating in the Healthcare sector within the Biotechnology industry. Founded in 1988 and built around a proprietary antibody-discovery and genetics research engine, Regeneron has grown into one of the largest independent biotech companies in the world, with total revenue of roughly $14-15.5 billion, a workforce of about 15,400 employees, and a market capitalization in the $80-90 billion range. Its portfolio spans ophthalmology, immunology and inflammation, oncology, cardiovascular and metabolic disease, and rare and infectious diseases, anchored by two blockbuster franchises — the eye-disease treatment Eylea/Eylea HD and the inflammatory-disease drug Dupixent (commercialized with partner Sanofi).

What They Do & How They Make Money

Regeneron makes money by researching, developing, and selling prescription biologic medicines — drugs made from living cells rather than chemically synthesized small molecules — and it earns revenue through two distinct channels. First, it directly sells and records revenue on products it commercializes itself in the United States, most notably Eylea and Eylea HD (injectable treatments for wet age-related macular degeneration and other retinal diseases) and Libtayo (an immuno-oncology therapy for certain skin, lung, and cervical cancers). Second, and increasingly important to its overall economics, it earns substantial collaboration revenue by partnering with larger pharmaceutical companies to develop and commercialize additional medicines: Sanofi records global sales of Dupixent (for eczema, asthma, and other allergic/inflammatory conditions) and Kevzara, sharing profits with Regeneron under a long-standing antibody collaboration; and Bayer records sales of Eylea outside the United States, similarly sharing profits with Regeneron. This partnership model lets Regeneron leverage its own deep R&D and manufacturing capabilities while relying on partners' global commercial infrastructure to reach international and, in Dupixent's case, broader U.S. markets, and it reinvests heavily in R&D (several billion dollars annually) to keep its pipeline of new antibody and genetic-medicine candidates moving through clinical trials.

Business Segments

Regeneron does not report discrete financial reporting segments in the way a diversified conglomerate would; it operates as a single integrated biopharmaceutical business, but its revenue and pipeline are best understood by product/therapeutic franchise:

Ophthalmology (Eylea / Eylea HD) — Regeneron's largest legacy franchise, treating wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Combined U.S. Eylea and Eylea HD net product sales were roughly $4.4 billion in 2025, though standard Eylea sales have declined sharply (down over 40% in 2025) due to biosimilar competition, while the newer, longer-acting Eylea HD has been growing quickly and is intended to offset that decline. Bayer separately generates about $1.4 billion in collaboration revenue for Regeneron from ex-U.S. Eylea sales.
Immunology & Inflammation (Dupixent, via Sanofi collaboration) — Regeneron's largest overall revenue contributor by economics, generating close to $5.9 billion in collaboration/profit-share revenue in 2025 from global Dupixent (and Kevzara) sales that Sanofi records on its own books; Dupixent itself is now one of the best-selling drugs in the world, approved across a growing list of allergic and inflammatory indications.
Oncology (Libtayo and pipeline) — Immuno-oncology therapies, led by Libtayo (roughly $1.5 billion in global sales in 2025), alongside a pipeline of bispecific antibodies and other cancer immunotherapies in development.
Cardiovascular/Metabolic, Rare Disease, and Other Products — Includes Praluent (cholesterol-lowering, partnered with Sanofi) and other smaller marketed products, plus an active pipeline of genetic-medicine and antibody candidates targeting rare and metabolic diseases, developed in part using Regeneron's proprietary VelocImmune and genetics-research platforms (including insights from the Regeneron Genetics Center).

Competitors

Ophthalmology: Roche/Genentech (Vabysmo), Novartis (Beovu), and a growing field of Eylea biosimilar makers (including Amgen's Pavblu, Samsung Bioepis, Formycon, and others now approved in the U.S.) compete directly with Eylea/Eylea HD, and biosimilar erosion has been the single biggest headwind to Regeneron's ophthalmology revenue.
Immunology/inflammation: AbbVie (Rinvoq, Skyrizi), Sanofi's own broader portfolio positioning, Eli Lilly (Ebglyss for atopic dermatitis, and other pipeline immunology assets), and Amgen compete with Dupixent across its various approved indications (atopic dermatitis, asthma, chronic rhinosinusitis, COPD, and prurigo nodularis, among others).
Oncology: Merck (Keytruda) and Bristol Myers Squibb (Opdivo) dominate the checkpoint-inhibitor category in which Libtayo competes, alongside numerous other immuno-oncology developers.
Broader biotech/pharma R&D competition: Amgen, Vertex Pharmaceuticals, Gilead Sciences, Novo Nordisk, and Eli Lilly compete more generally for scientific talent, licensing/partnership deals, and next-generation therapeutic modalities (gene editing, cell therapy, GLP-1-class metabolic drugs) as the industry continues shifting toward genetics-driven drug discovery.

Competitive Position

Regeneron's core competitive advantage is its in-house scientific and technology platform — most notably its VelocImmune humanized-mouse antibody-discovery technology and the Regeneron Genetics Center, one of the largest human genetics sequencing efforts in the world — which has historically let it originate novel biologic drugs faster and more efficiently than many peers, and has produced a pipeline of over a dozen FDA-approved medicines. Its partnership structure with Sanofi and Bayer gives it global commercial reach for Dupixent and international Eylea sales without having to build out a full-scale international sales force itself, while its Eylea HD and Libtayo franchises give it direct U.S. commercial capability as well. Dupixent's continued indication expansion and strong growth trajectory remains a major offsetting strength even as legacy Eylea faces biosimilar erosion.

The most significant near-term risk is exactly that biosimilar and next-generation competitive pressure on Eylea, which has already driven a sharp decline in standard Eylea sales and requires Eylea HD (and pipeline follow-ons) to succeed in defending the franchise. Regeneron is also more concentrated than many large pharma peers — a large share of its economics still flows from just two franchises (Eylea/Eylea HD and Dupixent) — which makes it more exposed than a highly diversified pharma giant to setbacks in either drug's competitive or regulatory trajectory. Additional risks common to the biotech industry include clinical trial failure risk across its development pipeline, pricing and reimbursement pressure (including U.S. drug-pricing policy and Medicare negotiation provisions under the Inflation Reduction Act), manufacturing and supply chain complexity inherent to biologics production, and patent-cliff/exclusivity risk as key products age and attract biosimilar or generic competition over time.